|
|
Home > Healthcare > Pharmaceutical > Oncology & Hematology
Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy
|
| Published Date:
October 2009
Published By:
Datamonitor
Page Count:
199
Order Code:
R313-55071
|
|
|
|
Introduction
The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic leukemia (ALL) is largely based on chemotherapy regimens that have changed little in the past few decades. Patient outcomes for both diseases remain poor, particularly for elderly and high-risk patients. As the limits of cytotoxic chemotherapy are being reached, an unmet need remains for novel, improved therapies.
Scope- Analysis of the AML and adult ALL market based on a survey of 180 acute leukemia specialists, supported by interviews with key opinion leaders.
- Segmentation of the AML and adult ALL populations by age group and risk group, respectively
- In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for AML and adult ALL by age group and risk group, respectively
- Discussion of unmet needs and overview of late-stage pipeline drugs and marketed drugs investigated for expansion into the AML and adult ALL settings
Highlights
The only molecular targeted therapy approved for use in AML is Mylotarg (gemtuzumab ozogamicin; Wyeth) but it's use is limited to elderly, relapsed patients who are not candidates for other chemotherapy. A number of molecular targeted therapies are currently in development for AML but are expected to have minimal impact on patient outcomes.
Gleevec (imatinib; Novartis) is the only molecular targeted therapy used extensively in the treatment of adult ALL. To date, the second generation tyrosine kinase inhibitors Sprycel (dasatinib; Bristol-Myers Squibb) and Tasigna (nilotinib; Novartis) have limited use in the treatment of the disease.
Hematopoietic stem cell transplantation (HSCT) has a central role in the management of both AML and adult ALL. However, it remains an underutilized procedure and its use is often delayed beyond its optimal timing. Research efforts are required to optimize the use of this potentially curative approach.
Reasons to Purchase- Understand prescribing trends in the AML and adult ALL markets
- Examine unmet need within the AML and adult ALL markets and identify opportunities for new product development
- Enhance commercial positioning by increasing understanding of current dynamics within the AML and adult ALL markets
Please note: this is delivered as a Zip file.
|
Similar Products
• Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence
• Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
• CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer
• Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
Published Oct 2009 by Datamonitor
• Top 20 Cancer Therapy Brands Forecast
Published Oct 2009 by Datamonitor
• Forecast Insight: Top 20 Cancer Therapy Brands Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff
Published Sep 2009 by Datamonitor
• Strategic Analysis of the Bladder Cancer Therapeutics
Published Sep 2009 by Intellent
• Cancer Liver Cancer Therapy Area Pipeline Report
Published Sep 2009 by Life Science Analytics (LSA)
• Cancer Prostate Cancer Therapy Area Pipeline Report
Published Sep 2009 by Life Science Analytics (LSA)
|
|
|
|
0 items
